Clinical-stage biopharma Addex raises $2.8M via share sale, pushing operational runway to Q4 2027.
Addex Therapeutics raised $2.8M (CHF 2.2M) through an At-the-Market (ATM) offering, selling 437.87K American Depositary Shares (ADSs). The proceeds extend the company’s cash runway into Q4 2027, providing additional financial flexibility for clinical development.
The transaction increases Addex’s outstanding share count to 210.29M, excluding treasury shares, while total issued shares remain at 218.65M. The ATM agreement was executed with H.C. Wainwright & Co., supporting the firm’s ongoing pipeline advancement.
No immediate market reaction was disclosed following the announcement.